HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IFF first quarter

This article was originally published in The Rose Sheet

Executive Summary

North American functional fragrance sales rose 20% in Q1 based on "new wins," but 20% decline in fine fragrance revenues led to flat fragrance performance overall for the region, excluding businesses divested in 2001, Chief Financial Officer Doug Wetmore states during April 25 financial report. European fragrance sales declined 1% in dollar terms, pulled down by high single-digit decrease in fine fragrances. Worldwide fragrance sales off 3% during quarter on pro forma basis, excluding businesses sold in late 2001 and reflecting new accounting rules for goodwill and intangibles, according to firm's April 25 1sales and earnings release. Consolidated sales of $445.8 mil. for Q1 were down 3.9% on pro forma basis. Net earnings doubled to $41.9 mil., up from $20.3 mil. in previous-year period...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010240

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel